# REJOICE-Ovarian01

Source: https://onco.cc/trials/rejoice-ovarian01/  
OnCo record `rejoice-ovarian01` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tests whether a CDH6-targeting ADC with Enhertu's payload can beat chemotherapy in resistant ovarian cancer.

## Summary

REJOICE-Ovarian01, trial NCT06161025 sponsored by Daiichi Sankyo and Merck, is the phase 2/3 test of whether raludotatug deruxtecan, a CDH6-targeting antibody-drug conjugate carrying the same payload as trastuzumab deruxtecan, can beat physician's choice chemotherapy in platinum-resistant ovarian cancer after one to three prior lines. The phase 2 dose-optimisation part reported an objective response rate of 50.5 percent at ESMO 2025, the phase 3 part randomises at 5.6 mg/kg against chemotherapy, and readout is expected in 2026 to 2027. OnCo links it to ovarian cancer, antibody-drug conjugates, CDH6 as a target and raludotatug deruxtecan. Whether a new ADC target can match mirvetuximab's survival benefit, and in which patients, is the question it will answer.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-07
- Registry id: NCT06161025
- Phase: 2/3
- Setting: Platinum-resistant ovarian cancer, 1-3 prior lines: raludotatug deruxtecan (CDH6 ADC) vs physician's-choice chemotherapy
- Sponsor: Daiichi Sankyo / Merck
- Result: Phase 2 ORR 50.5%; phase 3 ongoing.
- Outcomes: Objective response rate (phase 2 part): R-DXd 50.5%

## Sources

- ClinicalTrials.gov NCT06161025: https://clinicaltrials.gov/study/NCT06161025

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [CDH6](https://onco.cc/targets/cdh6/)
- drugs: [Raludotatug deruxtecan](https://onco.cc/drugs/raludotatug-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)
- terms: [Dose-escalation designs (3+3, BOIN, dose-expansion)](https://onco.cc/terms/dose-escalation-design/), [Phase 1, 2 and 3 trials](https://onco.cc/terms/trial-phases/), [Project Optimus](https://onco.cc/terms/project-optimus/), [Seamless, adaptive and Bayesian trial designs](https://onco.cc/terms/seamless-adaptive/)

---
JSON: https://onco.cc/api/v1/entities/rejoice-ovarian01.json